HomepageEVGN • NASDAQ
add
Evogene Ltd
$ 0,79
Na sluitingstijd:(2,72%)+0,021
$ 0,81
Gesloten: 5 mrt, 18:00:01 GMT-5 · USD · NASDAQ · Disclaimer
Vorige slotkoers
$ 0,84
Dag-range
$ 0,73 - $ 0,84
Jaar-range
$ 0,73 - $ 2,42
Beurswaarde
6,84 mln. USD
Gem. volume
835,28K
Koers/winst
-
Dividendrendement
-
Primaire beurs
NASDAQ
In het nieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
| (USD) | sep 2025info | Wijziging j-o-j |
|---|---|---|
Opbrengst | 312,00K | -82,63% |
Bedrijfskosten | 2,88 mln. | -64,76% |
Netto inkomsten | 3,87 mln. | 150,77% |
Netto winstmarge | 1,24K | 392,27% |
Winst per aandeel | -0,46 | 64,51% |
EBITDA | -2,44 mln. | 64,22% |
Effectief belastingtarief | -0,04% | — |
Balans
Totale activa
Totale passiva
| (USD) | sep 2025info | Wijziging j-o-j |
|---|---|---|
Contanten en kortetermijnbeleggingen | 15,96 mln. | -20,02% |
Totale activa | 26,09 mln. | -34,97% |
Totale passiva | 8,83 mln. | -68,31% |
Totaal aandelenvermogen | 17,25 mln. | — |
Uitstaande aandelen | 8,72 mln. | — |
Koers-boekwaardeverhouding | 6,45 | — |
Rendement op activa | -22,70% | — |
Rendement op kapitaal | -39,13% | — |
Kasstroom
Nettomutatie in liquide middelen
| (USD) | sep 2025info | Wijziging j-o-j |
|---|---|---|
Netto inkomsten | 3,87 mln. | 150,77% |
Operationele kasstroom | -3,33 mln. | 32,37% |
Kasstroom uit beleggingen | 10,91 mln. | 441,12% |
Kasstroom uit financiering | -10,34 mln. | -318,34% |
Nettomutatie in liquide middelen | -2,70 mln. | -247,46% |
Vrije kasstroom | -385,62K | -131,18% |
Over
Evogene is a computational chemistry company based in Israel, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries. At the core of its technology is ChemPass AI, a proprietary generative AI engine that enables the design of novel, highly potent small molecules optimized across multiple critical parameters. This powerful platform significantly improves success rates while reducing development time and costs. Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products driven by the integration of scientific innovation with real-world industry needs.
In 2024, the company began collaborating with Google Cloud to develop an AI-powered generative model aimed at discovering small molecules for drug development and sustainable agriculture. Wikipedia
CEO
Opgericht
1999
Website
Werknemers
117